Antiplatelet Resumption After Alteplase in Acute Ischemic Stroke
Antiplatelet therapy should be started 24 hours after alteplase administration, following a follow-up CT or MRI scan to exclude hemorrhagic transformation. 1
Standard Protocol for Antiplatelet Resumption
The American Heart Association/American Stroke Association guidelines establish a clear timeline:
- Obtain neuroimaging at 24 hours post-alteplase (CT or MRI scan) before initiating any antiplatelet or anticoagulant therapy 1
- Start antiplatelet therapy after 24 hours if imaging excludes intracranial hemorrhage 1
- Avoid antiplatelet therapy within the first 24 hours as standard practice to minimize bleeding risk 1
This 24-hour waiting period is based on the pharmacodynamics of alteplase and the peak risk window for symptomatic intracranial hemorrhage, which occurs within the first 24-36 hours post-thrombolysis. 1
Evidence Against Early Antiplatelet Administration
The risk of early antiplatelet therapy (<24 hours) outweighs potential benefits:
- A randomized controlled trial (ARTIS trial) demonstrated that intravenous aspirin 300 mg given within 90 minutes of alteplase significantly increased symptomatic intracranial hemorrhage (4.3% vs 1.6%, p=0.04) without improving functional outcomes at 3 months 2
- Symptomatic intracranial hemorrhage was more often the cause of poor outcomes in the early aspirin group compared to standard treatment (11 vs 1 patients, p=0.006) 2
- The trial was terminated prematurely due to excess bleeding with no evidence of benefit 2
Uncertain Clinical Scenarios
When concomitant high-risk conditions exist (e.g., acute coronary syndrome, recent coronary stent), the decision becomes more nuanced:
- The 2018 AHA/ASA guidelines state that early antithrombotic use (<24 hours) "might be considered" only when withholding treatment poses substantial risk from the concomitant condition (Class IIb, Level B-NR) 1
- A retrospective Korean study found no increased hemorrhage risk with early antiplatelet initiation, but this was subject to selection bias and requires individualized risk-benefit assessment 1
- More recent retrospective data (2022) in patients receiving alteplase alone showed no increased symptomatic intracranial hemorrhage with early antiplatelet therapy, but this requires prospective validation 3
These scenarios remain exceptions, not the rule—the default remains waiting 24 hours.
Monitoring Requirements During the 24-Hour Window
Critical monitoring parameters before antiplatelet initiation: 1
- Blood pressure control: Maintain BP <180/105 mm Hg for at least 24 hours post-alteplase 1
- Neurological assessments: Every 15 minutes during and for 2 hours after infusion, then every 30 minutes for 6 hours, then hourly until 24 hours 1
- Emergency imaging: Obtain immediate CT if patient develops severe headache, acute hypertension, nausea, vomiting, or neurological worsening 1
Choice of Antiplatelet Agent After 24 Hours
For most patients with acute ischemic stroke:
- Aspirin monotherapy (81-325 mg daily) is the standard choice for long-term secondary prevention after the 24-hour window 1
- Dual antiplatelet therapy (aspirin + clopidogrel) is only indicated for minor stroke (NIHSS ≤3) or high-risk TIA, and must be initiated within 24-72 hours of symptom onset to provide benefit 4, 5
- DAPT is contraindicated in moderate-to-severe stroke (NIHSS >3) at any timepoint, including after alteplase 4
Common Pitfalls to Avoid
- Do not start antiplatelet therapy before 24 hours based on perceived urgency—the bleeding risk is real and documented 2
- Do not skip the 24-hour imaging—hemorrhagic transformation may be clinically silent 1
- Do not initiate DAPT after 2 weeks post-stroke—the therapeutic window for DAPT benefit closes within 21-30 days, and late initiation provides no benefit over monotherapy 4
- Do not use DAPT in large vessel strokes—these typically have NIHSS >3, making them ineligible regardless of timing 4